This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wodarz, D. Search for Related Content PubMed PubMed Citation Articles by Wodarz, D.

Viruses as Antitumor Weapons

Defining Conditions for Tumor Remission

Institute for Advanced Study, Princeton, New Jersey 08540

Recent research has indicated that viruses specifically infecting tumor cells could be used as an alternative therapeutic approach in cancer patients. A particular example is the adenovirus ONYX-015, which has entered clinical trials in the context of head and neck cancer. Successful therapy crucially requires an understanding about how viral and host parameters influence tumor load. The interactions between the growing tumor, the replicating virus, and possible immune responses are multifactorial and nonlinear. Hence, a complete understanding of how virus and host characteristics influence the outcome of therapy requires mathematical models. In this study, such mathematical models are presented and analyzed. The study investigates three possible scenarios that could be relevant for therapy: (a) viral cytotoxicity alone kills tumor cells; (b) a virus-specific lytic CTL response contributes to killing of infected tumor cells; (c) the virus elicits immunostimulatory signals within the tumor that promote the development of tumor-specific CTL. The models precisely define conditions required for successful therapy. They identify the parameters that need to be measured and modulated to evaluate and refine the existing therapy regimes.

This article has been cited by other articles:

				W. Mok, T. Stylianopoulos, Y. Boucher, and R. K. Jain Mathematical Modeling of Herpes Simplex Virus Distribution in Solid Tumors: Implications for Cancer Gene Therapy Clin. Cancer Res., April 1, 2009; 15(7): 2352 - 2360. [Abstract] [Full Text] [PDF]

				D. Wodarz Use of oncolytic viruses for the eradication of drug-resistant cancer cells J R Soc Interface, February 6, 2009; 6(31): 179 - 186. [Abstract] [Full Text] [PDF]

				L. R. Paiva, C. Binny, S. C. Ferreira Jr., and M. L. Martins A Multiscale Mathematical Model for Oncolytic Virotherapy Cancer Res., February 1, 2009; 69(3): 1205 - 1211. [Abstract] [Full Text] [PDF]

				X. Huang, L. Zhuang, Y. Cao, Q. Gao, Z. Han, D. Tang, H. Xing, W. Wang, Y. Lu, G. Xu, et al. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration Mol. Cancer Ther., June 1, 2008; 7(6): 1624 - 1632. [Abstract] [Full Text] [PDF]

				J. J Bull and R. R Regoes Pharmacodynamics of non-replicating viruses, bacteriocins and lysins Proc R Soc B, November 7, 2006; 273(1602): 2703 - 2712. [Abstract] [Full Text] [PDF]

				T. Wirth, F. Kuhnel, B. Fleischmann-Mundt, N. Woller, M. Djojosubroto, K. L. Rudolph, M. Manns, L. Zender, and S. Kubicka Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1 Cancer Res., August 15, 2005; 65(16): 7393 - 7402. [Abstract] [Full Text] [PDF]

				D. Wodarz Correspondence re: L. M. Wein et al., Validation and Analysis of a Mathematical Model of a Replication-Competent Oncolytic Virus for Cancer Treatment: Implications for Virus Design and Delivery. Cancer Res., 63: 1317-1324, 2003. Cancer Res., December 1, 2003; 63(23): 8554 - 8554. [Full Text] [PDF]

				T. P. Padera, Y. Boucher, R. K. Jain, L. M. Wein, P. E. Holden, and D. H. Kirn Correspondence re: S. Maula et al., Intratumoral Lymphatics Are Essential for the Metastatic Spread and Prognosis in Squamous Cell Carcinoma of the Head and Neck. Cancer Res., 63: 1920-1926, 2003. Cancer Res., December 1, 2003; 63(23): 8555 - 8557. [Full Text] [PDF]

				L. M. Wein, J. T. Wu, and D. H. Kirn Validation and Analysis of a Mathematical Model of a Replication-competent Oncolytic Virus for Cancer Treatment: Implications for Virus Design and Delivery Cancer Res., March 15, 2003; 63(6): 1317 - 1324. [Abstract] [Full Text] [PDF]

				K.-W. Peng, C. J. TenEyck, E. Galanis, K. R. Kalli, L. C. Hartmann, and S. J. Russell Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus Cancer Res., August 15, 2002; 62(16): 4656 - 4662. [Abstract] [Full Text] [PDF]

				K. C. Erlach, J. Podlech, A. Rojan, and M. J. Reddehase Tumor Control in a Model of Bone Marrow Transplantation and Acute Liver-Infiltrating B-Cell Lymphoma: an Unpredicted Novel Function of Cytomegalovirus J. Virol., February 22, 2002; 76(6): 2857 - 2870. [Abstract] [Full Text] [PDF]

				Y. Tong, Q. Yang, C. Vater, L.K. Venkatesh, D. Custeau, T. Chittenden, G. Chinnadurai, and H. Gourdeau The Pro-apoptotic Protein, Bik, Exhibits Potent Antitumor Activity That Is Dependent on Its BH3 Domain Mol. Cancer Ther., December 1, 2001; 1(2): 95 - 102. [Abstract] [Full Text] [PDF]